PMID: 2110206Jan 1, 1990Paper

A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder

International Clinical Psychopharmacology
J CottrauxP Cialdella

Abstract

DSM-3 obsessive-compulsive out-patients were randomly assigned to fluvoxamine with antiexposure (F), fluvoxamine with exposure (Fe), or placebo with exposure (Pe) for 24 weeks. Of 65 patients offered treatment 60 entered the trial, 50 reached week 8, 44 completed treatment to week 24, and 37 reached follow up to week 48. On average the patient had depressed mood (mean Hamilton depression rating scale = 19). Drop-out numbers, clinical status and behavioural measures were comparable across groups. Most F patients did not do antiexposure, but Fe and Pe patients complied in doing exposure. All three groups improved in rituals and depression from week 0 to week 24 and 48, with a slight but non-significant superiority for combined treatment up to week 24. At week 8 there was a drug between-group effect on rituals, but not on depression. At week 24 there was a drug between-group effect on depression, but not on rituals. The drug superiority was short-lived. At week 48 there was no between-group difference in rituals or depression. Depression was related to ritual outcome at week 24 in F, and tended to be so in Fe.

Citations

Apr 17, 2001·Depression and Anxiety·D L Dunner
Jul 21, 2004·Current Psychiatry Reports·John M Kuzma, Donald W Black
Aug 16, 2005·Current Psychiatry Reports·Jonathan D Huppert, Martin E Franklin
Apr 25, 2012·Current Psychiatry Reports·Dan J SteinH Blair Simpson
Jun 1, 1993·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·S A MontgomeryA J Wood
May 1, 1996·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·J J López-IborJ C Gómez-Pérez
Jan 1, 1997·European Psychiatry : the Journal of the Association of European Psychiatrists·R L Holland
Jul 26, 2003·Journal of Child and Adolescent Psychopharmacology·Jennifer B FreemanHenrietta L Leonard
Oct 6, 2007·International Clinical Psychopharmacology·Naomi A FinebergDan J Stein
Jun 27, 1992·BMJ : British Medical Journal·J G Edwards
Aug 29, 2009·International Journal of Cognitive Therapy·Stefan G HofmannJasper A J Smits
Oct 25, 2008·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Borwin BandelowJohann Vega
Nov 1, 2006·Journal of Traumatic Stress·Michael DavisStephen Southwick
Aug 16, 2008·The Mount Sinai Journal of Medicine, New York·Heather A BerlinEric Hollander
Sep 6, 2012·Brain and Behavior·Xian-Zhang HuShu-Fan Wang
Nov 14, 2015·Annual Review of Clinical Psychology·Edna B Foa, Carmen P McLean
Mar 22, 2015·Clinical Psychology Review·Rebecca L SchneiderKate B Wolitzky-Taylor
Jul 6, 2010·The Psychiatric Clinics of North America·K A GanasenD J Stein
Nov 6, 2012·The Australian and New Zealand Journal of Psychiatry·Naomi A FinebergIlenia Pampaloni
Jul 27, 2004·Depression and Anxiety·H Blair SimpsonRaphael Campeas
Apr 11, 2006·Acta Psychiatrica Scandinavica·K P O'ConnorP Doucet
Feb 7, 2008·The Cochrane Database of Systematic Reviews·G M SoomroM Oakley-Browne
Apr 1, 1995·The British Journal of Psychiatry : the Journal of Mental Science·M PiccinelliG Wilkinson
Jan 1, 2014·Expert Review of Neurotherapeutics·Shyam Sundar Arumugham, Y C Janardhan Reddy
Feb 5, 2019·The International Journal of Risk & Safety in Medicine·P B DanborgP C Gøtzsche
Feb 20, 1998·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·I Marks
Feb 10, 2004·CNS Spectrums·John H GreistUNKNOWN World Council of Anxiety
Feb 10, 2004·CNS Spectrums·Joseph Zohar, UNKNOWN World Council of Anxiety
May 1, 1994·Psychiatry·P R MunfordR P Liberman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.